Rendu-Osler-Weber syndrome: dermatological approach*

Aline Blanco Barbosa1 Günter Hans Filho2 Carolina Faria dos Santos Vicari1 Marcelo Zanolli Medeiros2 Dâne Vargas Couto2 Luiz Carlos Takita2

DOI: http://dx.doi.org/10.1590/abd1806-4841.20152563

Abstract: The Rendu-Osler-Weber syndrome is a rare systemic fibrovascular dysplasia, recognized by mucocutaneous telangiectasias, arteriovenous malformations, epistaxis and family history. Recurrent bleeding, hypoxemia, congestive heart failure, portosystemic encephalopathy, and symptoms related to angiodysplasia of the central nervous system may occur. Since the treatment is based on supportive measures, early recognition is of utmost importance. This article reports the case of a 53-year-old male patient who presented telangiectasias on fingers, oral cavity and nasal mucosa for 10 years, with a history of recurrent epistaxis of varying severity since childhood. Mother, sister and daughter have similar lesions.

Keywords: Epistaxis; Genetics; Telangiectasia, hereditary hemorrhagic

INTRODUCTION

The Rendu-Osler-Weber syndrome, also known as Hereditary Hemorrhagic Telangiectasia (HHT) is a rare systemic fibrovascular dysplasia, characterized by recurrent epistaxis, mucocutaneous telangiectasias, arteriovenous malformations (AVMs) in different organs and family history.

Its incidence is 1-2/100,000 homogeneously distributed by race and sex. It has autosomal dominant transmission and high degree of penetrance, but there is no family history in around 20% of cases.1

Mutations in two genes are considered as responsible for the majority of cases: endoglin (ENG) located on chromosome 9q33-q34 and activin receptor-like kinase (ALK1) located on chromosome 12q13.2 ENG mutations are observed in HHT type 1, phenotype responsible for 40% of pulmonary AVMs whereas mutations of ALK1 are observed in HHT type 2, leading to lower incidence of these AVMs (14%) associated with milder forms and late onset of the disease.3 The mutated genes encode proteins that modulate transforming growth factor beta (TGF-β), which stimulates vascular endothelial growth factor (VEGF) production and plays a key role in angiogenesis.4 Diagnosis is based on the Curaçao criteria:5

1) Epistaxis, spontaneous, recurrent nosebleeds;
2) Telangiectasias - multiple, at characteristic sites (lips, oral cavity, fingers, none);
3) **Visceral lesions** - such as gastrointestinal telangiectasias (with or without bleeding), pulmonary AVM, hepatic AVM, cerebral AVM, spinal AVM; and
4) **Family history** - a first-degree relative with HHT.

Three criteria indicate a definite diagnosis of the disorder; two a possible or suspected case.

The treatment is only palliative, with no consensus on the best treatment option. It is essential to promote control of the disease as long as possible.

**CASE REPORT**

Male patient, 53 years old, presented vegetating plaque on the back of the tongue and telangiectasias on the lips, gums, palate, oral and nasal mucosa as well as on fingers for 10 years (Figure 1). He complains also of recurrent epistaxis of varying intensity ever since his childhood. Routine laboratory tests showed mild anemia and iron deficiency (hemoglobin 11.9 g/dL; serum iron levels 56 mcg/dL), since there was no major bleeding in the past months.

Mother (who died at age 45 due to stroke), sister and daughter have similar lesions. Histology of nasal injury point to vascular dilation and deposition of hemosiderin (Figure 2).

Bronchoscopy, esophagogastroduodenoscopy and colonoscopy show diffuse telangiectasias without signs of recent bleeding (Figures 3 and 4). As the most serious complaint of the patient was nose bleeding, he was referred to otolaryngology and is being monitored to exclude other possible foci of AVMs.

**DISCUSSION**

Hereditary Hemorrhagic Telangiectasia presents mucocutaneous macular telangiectasia with 1 to 3 mm of diameter that, generally, appears 10 to 30 years after epistaxis episodes (60% of patients). Palms and fingers are the only sites affected in 71% of patients, lips and tongue in 66%. Twenty to 40% have complete cutaneous manifestations, compatible with the present report, which met the four Curaçao criteria.

Pulmonary manifestations include hemoptysis, hemothorax, right-to-left-shunting and paradoxical emboli (venous circulation embolic event that reaches the systemic circulation). These symptoms arise from AVMs and fistulas, present in 5-23% of patients. The paradoxical embolism, found in 40-50% of patients, can cause transitory ischemic events and strokes. In 8% of patients, massive pulmonary hemorrhage can occur. Other symptoms include hypoxia, dyspnea, cyanosis, polycythemia and clubbing of the distal phalange.

Complications in the central nervous system (CNS) vary from transitory ischemic events to an abscess or intracranial bleeding. It is estimated that 8-41% of patients with HHT will present some neurological complication during their lifetime. Clinical manifestations may include convulsions, headache, coma and different degrees of neurological deficits.
In the gastrointestinal tract, manifestations include telangiectasias, AVMs and varicosities, which can lead to upper gastrointestinal bleeding, liver dysfunction and encephalopathy. Bleeding tends to be recurrent and progressive, usually occurring after 40 years of age.1

The treatment traditionally relies on surgical procedures, preferably endoscopic, to control iron deficiency anemia, bleeding and potentially lethal aneurysms, in addition to the use of hormonal therapies (estrogen and progesterone).6,7 In recent research, bevacizumab (anti-VEGF monoclonal antibody) has been evaluated with promising results, but it is still not considered definitive due primarily to its various long-term side effects.4

Prognosis is favorable in cases where the bleeding can be controlled, and the reported mortality due to disease complications is less than 10% of cases. Knowledge of dermatological aspects of this rare and potentially severe condition may be essential for early diagnosis, enabling the investigation of pulmonary and CNS malformations and preventing possible catastrophic effects of the disease. ❑

REFERENCES
1. Garcia RID, Cecotto SB, Costa KS, Veiga Jr FA, Ues JP, Rapoport PB. Síndrome de Rendu-Osler-Weber: tratamento clínico e cirúrgico. Rev Bras Otorrinolaringol. 2003;69:125-60.
2. Dupuis-Girod S, Bailly S, Plachez H. Hereditary hemorrhagic telangiectasia: from molecular biology to patient care. J Thromb Haemost. 2010;8:1447-56.
3. Sadick H, Sadick M, Gotta K, Naum R, Raciel F, Brusa G, et al. Hereditary hemorrhagic telangiectasia: an update on clinical manifestations and diagnostic measures. Wien Klin Wochenschr. 2006;118:72-80.
4. Bose P, Holter JL, Selby GB. Bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med. 2009;360:2143-4.
5. Fuchizaki U, Miyamori H, Kitagawa S, Kaneko S, Kobayashi K. Hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber disease). Lancet. 2003;362:1-4.
6. Juares AJC, Dell’Aringa AR, Nardi JC, Kobari K, Rodrigues VLMGM, Perches-Filho RM. Síndrome de Rendu-Osler-Weber: relato de caso e revisão da literatura. Rev Bras Otorrinolaringol. 2008;74:452-7.
7. Gontijo B, Pereira LB, Silva CMR. Vascular malformations. An Bras Dermatol. 2004;79:7-25.